Sohyun Kim

Dr. Sohyun Kim

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
Min Cheol ChangMin Cheol Chang
Min Cheol Chang
YCYoo Jin Choo
Yoo Jin Choo
SKSohyun Kim
Sohyun Kim
Chang MC, et al. Ann Surg Treat Res. 2023 Jun;104(6):313-324. https://doi.org/10.4174/astr.2023.104.6.313

31 October 2019 in Annals of Coloproctology
Verified
Journal Article
Open access
PDF file
MJMyunghoon Jeon
Myunghoon Jeon
KSKihwan Song
Kihwan Song
JKJail Koo
Jail Koo
SKSohyun Kim
Sohyun Kim
We assessed the clinical outcomes of a seton procedure combined with early versus late institution of infliximab (IFX) therapy. This retrospective study comprised 76 patients who underwent surgery for perianal fistula associated with Crohn disease between January 2014 and November 2017. All patients underwent loose seton drainage combined with IFX therapy. Patients categorized as the early group (EG, 49 patients) received IFX therapy within 30 days of completion of the seton procedure. Patients categorized as the late group (LG, 27 patients) received IFX therapy >30 days after the seton procedure. IFX therapy was administered as induction and maintenance therapy. There were no statistically significant intergroup differences in clinical characteristics of the patients. The mean follow-up was 21.0 ± 11.6 months in the EG and 34.5 ± 18.4 months in the LG (P = 0.001). The mean interval between seton procedure and IFX induction therapy was 12.2 days in the EG and 250.2 days in the LG (P = 0.002). Complete remission was observed in 32 patients (65.3%) in the EG and 17 patients (63.0%) in the LG (P = 0.844). Fistula recurrence was observed in 6 patients (7.9%). All recurrences occurred in a previous perianal fistula tract. Patients showed a good response to a seton procedure combined with IFX therapy regardless of the time of initiation of IFX therapy.

1 January 2023 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
SKSung Il Kang
Sung Il Kang
SKSohyun Kim
Sohyun Kim
Kang SI, et al. Ann Surg Treat Res. 2023 Sep;105(3):126-132. https://doi.org/10.4174/astr.2023.105.3.126

31 August 2019 in Annals of Coloproctology
Verified
Journal Article
Open access
PDF file
CKCho Shin Kim
Cho Shin Kim
SKSohyun Kim
Sohyun Kim
We assessed the oncologic and anastomotic benefits of low ligation of the inferior mesenteric artery (IMA) with additional lymph node (LN) retrieval. We performed a retrospective case-control study between January 2011 and July 2015. All patients underwent curative resection of a primary sigmoid or rectal tumor. We excluded patients with distant metastases at the time of diagnosis. The case group included patients who underwent high ligation of the IMA (high group, HG). The control group included patients who underwent low ligation of the IMA with low group with additional LN retrieval (LGAL). Controls were identified by matching patients based on age (±5 years), sex, tumor location, and final histopathological stage. Finally, each group included 97 patients. Clinical characteristics did not significantly differ between groups. The mean number of additional harvested LN was 2.19 (range, 0-11), and one patient in the LGAL had a metastatic LN among the additional harvested LN. The overall morbidity was 22.7% in the HG and 30% in the LGAL (P = 0.257). Anastomotic leakage occurred in 14 patients (14.4%) in the HG and 5 patients (5.2%) in the LGAL (P = 0.030). The mean disease-free survival time in the HG was longer than that in the LGAL (P = 0.008). The mean overall survival (OS) time was 70.4 ± 1.3 months. The mean OS was 63.7 ± 1.6 months in the HG and 69.1 ± 2.6 months in the LGAL (P = 0.386). Low ligation of the IMA with additional LN retrieval is technically safe. However, the oncologic effect was better after high ligation of IMA.

30 April 2024 in Annals of Coloproctology
Verified
Journal Article
Open access
PDF file
TLTae-Gyun Lee
Tae-Gyun Lee
GSGil-Hyeon Song
Gil-Hyeon Song
HAHong-Min Ahn
Hong-Min Ahn
HOHeung-Kwon Oh
Heung-Kwon Oh
MBMoonkyoung Byun
Moonkyoung Byun
O(on behalf of the Public Relations Committee of the Korean Society of Coloproctology (KSCP)
on behalf of the Public Relations Committee of the Korean Society of Coloproctology (KSCP)
Purpose: The Korean Society of Coloproctology has been conducting Colorectal Cancer Awareness Campaign, also known as the Gold Ribbon Campaign, every September since 2007. The 2022 campaign was held through a metaverse platform targeting the younger age group under the slogan of raising awareness of early-onset colorectal cancer (CRC). This study aimed to analyze the impact of the 2022 campaign on a metaverse platform.Methods: Anonymized survey data were collected from participants in the metaverse campaign from September 1 to 15, 2022. The satisfaction score of the participants was evaluated by sex, age group, and previous campaign participation status.Results: During the campaign, 2,770 people visited the metaverse. Among them, 455 people participated in the survey (response rate, 16.4%). Approximately 95% of the participants reported being satisfied with the information provided by the campaign, understood the necessity of undergoing screening for and prevention of early-onset CRC, and were familiar with the structure of the metaverse. The satisfaction score for campaign information tended to decrease as the participants’ age increased. When the participants’ overall level of satisfaction with the metaverse platform was assessed, teenagers scored particularly lower than the other age groups. The satisfaction scores for CRC information provided in the metaverse, as well as the scores for recognizing the seriousness and necessity of screening for early-onset CRC, indicated a high positive tendency (P<0.001).Conclusion: Most of the 2022 Gold Ribbon Campaign participants were satisfied with the metaverse platform. Medical society should pay attention to increasing participation in and satisfaction with future public campaigns.

1 December 2021 in Korean Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
KPKeehyun Park
Keehyun Park
SKSohyun Kim
Sohyun Kim
HLHye Won Lee
Hye Won Lee
SBSung Uk Bae
Sung Uk Bae
SBSeong Kyu Baek
Seong Kyu Baek
WJWoon Kyung Jeong
Woon Kyung Jeong
Purpose: This study aimed to evaluate and compare the quality of total mesorectal excision (TME) and disease-free and overall survival rates between robotic and laparoscopic surgeries for rectal cancer.Methods: From January 2015 to December 2018, 234 patients underwent curative robotic or laparoscopic surgery for rectal cancer at two centers. Ultimately, 201 patients were enrolled. To control for different demographic factors in the two groups, propensity score matching was used at a 1:1 ratio. Propensity scores were generated with the baseline characteristics, including age, sex, body mass index, American Society of Anesthesiologists score, previous abdominal surgery, tumor location, preoperative chemotherapy, and preoperative radiation. Finally, 134 patients were matched with 67 patients in the robotic surgery group and 67 patients in the laparoscopic surgery group.Results: There was no significant difference in the pathologic stages between the robotic and laparoscopic surgery groups. Distal margin involvement was only observed in the robotic surgery group (1/67, 1.5%). Circumferential resection margin involvement was not different between the robotic surgery and laparoscopic surgery groups (3/67 [4.5%] and 4/67 [6.0%], respectively, P = 1.000). The quality of TME (complete, nearly complete, and incomplete) was similar between the robotic surgery and laparoscopic surgery groups (88.0%, 6.0%, 6.0% and 79.1%, 9.0%, 11.9%, respectively, P = 0.358). The disease-free and overall survival rates were not significantly different between the groups.Conclusion: The quality of TME and disease-free and overall survival rates between the two surgeries were similar. There was no oncologic advantage of robotic surgery for rectal cancer compared to laparoscopic surgery.